Anzeige
❌
Mehr »
Donnerstag, 01.10.2026 - Börsentäglich über 12.000 News
Dieselbe Arbeit, dieselbe Rechnung, der vierfache Bruttogewinn
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 914178 | ISIN: US8688731004 | Ticker-Symbol: N/A
Frankfurt
18.11.25 | 08:04
36,400 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
SURMODICS INC Chart 1 Jahr
ACCESS Newswire
225 Leser
Artikel bewerten:
(1)

Surmodics Inc.: Surmodics Acquires Alta Biomed Business, Expanding Hemocompatible Surface Technology and Analytical Testing Capabilities

Acquisition adds proven PzF thin-film surface modification technology, specialized blood- and tissue-contacting device expertise and a West Coast testing facility

HORSHAM, PA / ACCESS Newswire / October 1, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced that it has acquired the business of Alta Biomed, a Carlsbad, California-based medical device coating and testing services company specializing in surface technologies for vascular and other medical devices.

The acquisition is a strategic addition to Surmodics' growing portfolio of hemocompatible and biocompatible surface technologies. It brings Alta Biomed's proprietary PzF thin-film surface modification technology to Surmodics, adding an established anti-thrombotic, anti-inflammatory and pro-healing option that joins Surmodics' existing hemocompatible portfolio.

"As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address increasingly complex blood-contacting applications," said Charlie Olson, President, Surmodics Coatings, Biomaterials and Catheter Technologies. "PzF gives our customers another proven thin-film surface modification to consider as they develop the next generation of devices."

PzF is an ultra-thin polymer surface modification technology designed to enhance hemocompatibility for blood and tissue-contacting medical devices and materials. With more than 20 years of history in medical device applications, PzF has received six FDA clearances and one PMA approval and is commercialized today in cardiovascular and embolization technologies. The technology can be applied to a variety of substrates ranging from metals, polymers, medical fabrics and even tissue. Device applications include stents, grafts, catheters, filters, nitinol devices, ePTFE devices and PET/polyester materials.

The acquisition also expands Surmodics' analytical testing capabilities. Alta Biomed's Carlsbad facility brings established expertise in hemocompatibility and particulate testing, including coating integrity assessment, acute particulate testing and dynamic human blood loop testing used to compare coated and uncoated devices.

With the acquisition complete, Surmodics has assumed Alta Biomed's ongoing operations in Carlsbad. The location expands Surmodics' geographic footprint and provides a West Coast presence closer to many medical device companies in California and the surrounding region. Existing Alta Biomed programs will continue as the company's PzF surface modification and testing capabilities are integrated into the broader Surmodics organization.

"This acquisition is a natural and exciting next step for our team. Joining Surmodics provides the scale, established leadership and global access to reach more patients with our advanced coating technologies," said Chris Nocera, VP of Engineering, Alta Biomed, who will lead the Carlsbad site.

The acquisition further advances Surmodics' strategy to build a differentiated portfolio of coating and surface modification technologies, specialty biomaterials and technical services that can support medical device companies from early feasibility and technology selection through testing, process development and commercialization.

About Alta Biomed

Alta Biomed, formerly Alta Biomaterials and a portfolio company of Nidus Biomedical, is a medical device coating services and testing company based in Carlsbad, California. The company specializes in PzF thin-film surface technology for vascular and other medical devices and works with medical device developers on coating feasibility, process development, coating integrity assessment, particulate testing and dynamic human blood loop testing. For more information visit www.altabiomed.com/.

About Surmodics

Surmodics provides performance coatings, surface technologies, specialty polymers, analytical testing, drug delivery and catheter development capabilities to the medical device industry. With nearly 50 years of experience in surface technology and biomaterials, Surmodics works with medical device developers to improve device performance and support programs from early-stage feasibility through commercialization. For more information, visit www.surmodics.com.

Media Contact

Jay Thompson
jay.thompson@surmodics.com

SOURCE: Surmodics Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/surmodics-acquires-alta-biomed-business-expanding-hemocompatible-surf-1229942

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.